Inclusion Criteria:

- Patients with advanced, metastatic and/or progressive solid tumors for whom there is
no effective standard therapy available (for part 2 in addition patients for whom
their PI3K pathway is deregulated)

- Evaluable or measurable disease

- Has normal organ function; is no greater than 2 on the ECOG performance scale

- Negative hCG test in women of childbearing potential

Exclusion Criteria:

- History of diabetes requiring daily medication or history of grade 3 or more fasting
hyperglycemia

- Patients with major surgery, radiotherapy, or immunotherapy within 4 weeks of
starting the study

- Clinical significant, unresolved toxicity from previous anti-cancer therapy

- Patients who previously received a MEK inhibitor (for combination part only)

- Presence of active gastrointestinal disease or other condition that will interfere
significantly with the absorption, distribution, metabolism, or excretion of drugs

- Known medical history of retinal vein occlusion, intraocular pressure greater than 21
mm Hg or patient considered at risk of retinal vein thrombosis (combination part
only)

- Known HIV positivity or active hepatitis B or C infection

- History of clinically significant cardiac condition